Report cover image

Asthma Therapeutics Market - By Drug Class, By Treatment Type, By Route of Administration (Inhaled, Oral, Injectable), By Distribution Channel, By End-use (Hospitals & clinics, ASCs, Homecare settings) - Global Forecast, 2024 - 2032

Publisher Global Market Insights
Published Mar 04, 2024
Length 200 Pages
SKU # GMI18789805

Description

Asthma Therapeutics Market - By Drug Class, By Treatment Type, By Route of Administration (Inhaled, Oral, Injectable), By Distribution Channel, By End-use (Hospitals & clinics, ASCs, Homecare settings) - Global Forecast, 2024 - 2032


Global Asthma Therapeutics Market will grow at 4.4% CAGR during 2024-2032, driven by increasing cases of asthma, innovations in medical technology, and government initiatives to tackle the ailment.

The increasing prevalence of asthma worldwide is a significant factor contributing to the growth of the Asthma Therapeutics Market. According to NIH, asthma affects approximately 300 million people globally, with its prevalence increasing by 50% every decade. Factors such as pollution, urbanization, and genetic predisposition have been the root causes of such a surge. Additionally, genetic predisposition further exacerbates the susceptibility to asthma among certain individuals.

This has led to a corresponding surge in demand for effective treatment options. Patients and healthcare providers alike are seeking innovative and efficient asthma therapeutics to manage the condition and alleviate symptoms, prompting pharmaceutical companies and healthcare providers to invest in R&D. As a result, the market is witnessing a proliferation of new treatment options aimed at addressing the evolving needs of patients and improving their quality of life.

The Asthma Therapeutics Market is classified based on drug class, treatment type, route of administration, distribution channel, end-use, and region.

Long-acting beta Agonists (LABA) from the drug class segment will gain notable traction by 2032, as these bronchodilators offer sustained relief from asthma symptoms by relaxing the muscles in the airways, allowing for improved airflow and symptom control. With their long duration of action and convenient dosing regimen, LABAs are widely used as maintenance therapy in combination with inhaled corticosteroids (ICS) for the long-term management of asthma. Additionally, the availability of LABA-containing combination inhalers simplifies treatment regimens and enhances patient adherence, driving market growth in this segment.

The asthma therapeutics market share from the quick relief medications segment will grow notably through 2032 as quick relief medications work by quickly relaxing the muscles in the airways, thus alleviating symptoms such as wheezing, coughing, and shortness of breath. These medications are typically used on an as-needed basis to provide immediate relief of acute asthma symptoms. With their fast-acting nature and widespread availability, SABAs remain a cornerstone of asthma management, inducing segment growth.

Asia Pacific Asthma Therapeutics Industry will expand at a decent pace through 2032, driven by rapid urbanization, industrialization, and environmental pollution. Additionally, increasing healthcare expenditure, expanding access to healthcare services, and growing awareness about asthma management will drive market growth in the region. With a large population base and a rising burden of respiratory diseases, APAC presents lucrative opportunities for pharmaceutical companies and healthcare providers operating in the region.

Table of Contents

200 Pages
Chapter 1 Methodology & Scope
1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast calculations
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Industry 360-degree synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Growing prevalence of asthma
3.2.1.2 Technological advancements
3.2.1.3 Rising expenditure on the R&D of novel biologics
3.2.1.4 Increase in awareness regarding asthma management
3.2.2 Industry pitfalls & challenges
3.2.2.1 Stringent regulatory requirements
3.2.2.2 Loss of patent protection for popular drugs
3.3 Growth potential analysis
3.4 Porter's analysis
3.4.1 Supplier power
3.4.2 Buyer power
3.4.3 Threat of new entrants
3.4.4 Threat of substitutes
3.4.5 Industry rivalry
3.5 PESTEL analysis
3.6 Reimburesemnt scenario
3.7 Regulatory landscape
3.8 Technological landscape
3.9 Future market trends
3.10 GAP analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Class, 2018 - 2032 ($ Mn)
5.1 Key trends
5.2 Combination therapies (ICS/LABAs)
5.3 Long-acting beta agonists (LABAs)
5.4 Short-acting beta agonists (SABAs)
5.5 Inhaled corticosteroids (ICS)
5.6 Oral and intravenous corticosteroids
5.7 Leukotriene modifiers
5.8 Other drug classes
Chapter 6 Market Estimates and Forecast, By Treatment Type, 2018 - 2032 ($ Mn)
6.1 Key trends
6.2 Long-term asthma control medications
6.3 Quick-relief (rescue) medications
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2018 - 2032 ($ Mn)
7.1 Key trends
7.2 Inhaled
7.3 Oral
7.4 Injectable
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Mn)
8.1 Key trends
8.2 Brick & mortar
8.3 Hospital pharmacies
8.4 E-commerce
Chapter 9 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)
9.1 Key trends
9.2 Hospitals & clinics
9.3 Ambulatory surgical centers
9.4 Homecare settings
Chapter 10 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)
10.1 Key trends
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Spain
10.3.5 Italy
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.4.6 Rest of Asia Pacific
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Argentina
10.5.4 Rest of Latin America
10.6 Middle East and Africa
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 UAE
10.6.4 Rest of Middle East and Africa
Chapter 11 Company Profiles
11.1 AstraZeneca
11.2 Boehringer Ingelheim
11.3 Cipla Ltd.
11.4 Covis Pharma
11.5 GSK plc
11.6 Merck & Co., Inc.
11.7 Novartis Pharmaceuticals Corporation
11.8 Regeneron Pharmaceuticals, Inc.
11.9 Sanofi
11.10 Teva Pharmaceutical Industries Ltd.

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us